BioSpace News Archive

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023.

VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease announced that the company has raised bridge financing to support its 2023 objectives.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announces publication of a landmark new clinical study which demonstrates the value creation associated with the rapid adoption of novel shoulder arthroplasty technologies.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”), announced today that they have completed the transaction to acquire Meridian.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced the close of its previously announced registered direct offering (the “Registered Direct Offering”) with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”) and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical -stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today provided an update on the TSHA-120 program in giant axonal neuropathy (GAN) and a corporate outlook for 2023.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.

Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2022.

Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.